GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » ROA %

CLPT (ClearPoint Neuro) ROA % : -42.89% (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ClearPoint Neuro's annualized Net Income for the quarter that ended in Sep. 2024 was $-19.90 Mil. ClearPoint Neuro's average Total Assets over the quarter that ended in Sep. 2024 was $46.38 Mil. Therefore, ClearPoint Neuro's annualized ROA % for the quarter that ended in Sep. 2024 was -42.89%.

The historical rank and industry rank for ClearPoint Neuro's ROA % or its related term are showing as below:

CLPT' s ROA % Range Over the Past 10 Years
Min: -93.09   Med: -50.51   Max: -27.15
Current: -38.96

During the past 13 years, ClearPoint Neuro's highest ROA % was -27.15%. The lowest was -93.09%. And the median was -50.51%.

CLPT's ROA % is ranked worse than
77.3% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -2.115 vs CLPT: -38.96

ClearPoint Neuro ROA % Historical Data

The historical data trend for ClearPoint Neuro's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro ROA % Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.00 -32.73 -30.31 -27.15 -45.01

ClearPoint Neuro Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.06 -42.72 -34.44 -33.20 -42.89

Competitive Comparison of ClearPoint Neuro's ROA %

For the Medical Devices subindustry, ClearPoint Neuro's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's ROA % distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's ROA % falls into.



ClearPoint Neuro ROA % Calculation

ClearPoint Neuro's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-22.089/( (55.49+42.661)/ 2 )
=-22.089/49.0755
=-45.01 %

ClearPoint Neuro's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-19.896/( (52.574+40.193)/ 2 )
=-19.896/46.3835
=-42.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


ClearPoint Neuro  (NAS:CLPT) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-19.896/46.3835
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-19.896 / 32.488)*(32.488 / 46.3835)
=Net Margin %*Asset Turnover
=-61.24 %*0.7004
=-42.89 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ClearPoint Neuro ROA % Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103